KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

Diamant Thaçi, Luis Puig, Sei-Ichiro Motegi, Kim Papp, Linda Stein Gold, Leon Kircik, Howard Sofen, Pablo Fernández-Peñas, Pedro Herranz, Christian Vestergaard, Yu-Huei Huang, Martin Dossenbach, Hany Elmaraghy, Gaia Gallo, Maria Jose Rueda, Marta Casillas, Chao Yang, Helena Agell, Meritxell Falqués, Audrey Nosbaum

Acta Derm Venereol 106 0160

PMID42163822
PMCIDPMC13191219
DOI10.2340/actadv.v106.adv-2025-0160
发表日期2026-05-21
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI). In clinical trials, percent EASI improvement is used to compare study arms and measure treatment effect size/impact. In clinical practice, however, absolute EASI scores are used (especially in Europe), as they measure an individual's disease state regardless of baseline severity. This post-hoc analysis assessed absolute EASI response - EASI≤7, ≤5, ≤3, and ≤1 - from the ADvocate trials to understand LEB efficacy in adults/adolescents with moderate-to-severe AD. Week-16 data from patients receiving LEB 250 mg Q2W (n=564) were compared with placebo (n=287). Across baseline moderate/severe/very severe EASI and baseline Investigator's Global Assessment (IGA) 3/4, significantly higher percentages of patients receiving LEB than those receiving placebo achieved each absolute EASI response. Week--16 LEB EASI 75 responders (n=284) and per-protocol LEB non-responders (n=215) were assessed through week 52. Absolute EASI scores were generally low and stable among responders and reduced among non-responders. Overall, LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Results reflect clinically meaningful improvements that could help guide clinical practice.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 4.

Fig. 4.. Response rates at week 52 among week-16 EASI 75 LEB responders. Each chart compares EASI response rates among week-16 EASI 75 LEB responders who were re-randomized into two LEB treatment arms and one LEB withdrawal arm. Data from weeks 16–52 are provided. Week-16 EASI 75 LEB responders who received systemic rescue medication, discontinued treatment due to lack of efficacy or transferred to the escape arm had values set to their baseline value after that time point through week 52. Those who received topical rescue medication or discontinued treatment for other reasons had values set to “missing” after that time point through week 52. Multiple imputation was used to handle missing data. Abbreviations: EASI, eczema area and severity index; LEB, lebrikizumab; Q2W, every 2 weeks; Q4W, every 4 weeks.

EASI_7

EASI ≤7 response rate

Fig. 4. · Panel EASI_7

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel EASI_7 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
EASI_5

EASI ≤5 response rate

Fig. 4. · Panel EASI_5

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel EASI_5 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
EASI_3

EASI ≤3 response rate

Fig. 4. · Panel EASI_3

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel EASI_3 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
EASI_1

EASI ≤1 response rate

Fig. 4. · Panel EASI_1

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel EASI_1 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1.. Week-16 absolute EASI response rates, LEB vs PBO. Each chart shows EASI response rates in the LEB 250 mg Q2W (purple) group vs the PBO (grey) group, with p <0.001 for all week-16 comparisons. Data after the use of rescue medication or discontinuation of treatment due to lack of efficacy were set to baseline value; remaining missing data were imputed using multiple imputation. Statistical tests were two-sided and were evaluated at a significance level of 0.05 using SAS software, version 9.4. Abbreviations: CI, confidence interval; EASI, Eczema Area and Severity Index; LEB, lebrikizumab; PBO, placebo; Q2W, every 2 weeks; SAS, Statistical Analysis System. *p <0.05; **p <0.01; ***p <0.001.
非 KM Figure
Fig. 2.Fig. 2.. Week-16 absolute EASI response rates by baseline EASI, LEB vs PBO. Each chart compares EASI response rates by baseline EASI in the LEB 250 mg Q2W group (purple) vs PBO group (grey). Data after the use of rescue medication or discontinuation of treatment due to lack of efficacy were set to baseline value; remaining missing data were imputed using multiple imputation. Statistical tests were two-sided and were evaluated at a significance level of 0.05 using SAS software, version 9.4. Abbreviations: CI, confidence interval; EASI, Eczema Area and Severity Index; LEB, lebrikizumab; PBO, placebo; Q2W, every 2 weeks; SAS, Statistical Analysis System. *p <0.05; **p <0.01; ***p <0.001.
非 KM Figure
Fig. 3.Fig. 3.. Week-16 absolute EASI response rates by baseline IGA score, LEB vs PBO. Each chart shows EASI response rates by baseline IGA score in the LEB 250 mg Q2W group (purple) vs the PBO group (grey). Data after the use of rescue medication or discontinuation of treatment due to lack of efficacy were set to baseline value; remaining data were imputed using multiple imputation. Statistical tests were two-sided and were evaluated at a significance level of 0.05 using SAS software, version 9.4. Abbreviations: CI, confidence interval; EASI, eczema area and severity index; IGA, investigator’s Global Assessment; LEB, lebrikizumab; PBO, placebo; Q2W, every 2 weeks; SAS, Statistical Analysis System. *p <0.05; **p <0.01; ***p <0.001.
非 KM Figure